Position of the Transparency Council – Cibinqo (abrocitinib)
At its meeting on 9 June 2025, the Transparency Council adopted position No. 70/2025 on the appraisal of drug Cibinqo (abrocitinib) under drug program B.124 “Treatment of patients with atopic dermatitis (ICD-10: L20)”
Publication of the position >>